Influenza Therapeutics
1. Rapivab patent expiration
Treatment: Treatment of acute uncomplicated influenza in patients 6 months and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6503745 | BIOCRYST | Cyclopentane and cyclopentene compounds and use for detecting influenza virus |
Nov, 2019
(6 years ago) | |
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(1 year, 3 months from now) | |
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Patient Population(NPP) | Sep 20, 2020 |
Drugs and Companies using PERAMIVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Dosage: SOLUTION
More Information on Dosage
RAPIVAB family patents
2. Relenza patent expiration
Treatment: Prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360817 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(12 years ago) | |
| US6294572 | GLAXOSMITHKLINE | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(11 years ago) | |
| US5648379 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(11 years ago) | |
Drugs and Companies using ZANAMIVIR ingredient
Market Authorisation Date: 26 July, 1999
Dosage: POWDER
More Information on Dosage
RELENZA family patents
3. Tamiflu patent
expiration
Treatment: Treatment and prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5952375 | ROCHE | Compounds and methods for synthesis and therapy |
Feb, 2015
(10 years ago) | |
| US5763483 | ROCHE | Carbocyclic compounds |
Dec, 2016
(9 years ago) | |
| US5866601 | ROCHE | Carbocyclic compounds |
Feb, 2016
(9 years ago) | |
|
US5952375 (Pediatric) | ROCHE | Compounds and methods for synthesis and therapy |
Aug, 2015
(10 years ago) | |
|
US5763483 (Pediatric) | ROCHE | Carbocyclic compounds |
Jun, 2017
(8 years ago) | |
|
US5866601 (Pediatric) | ROCHE | Carbocyclic compounds |
Aug, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-90) | Feb 22, 2013 |
| New Patient Population(NPP) | Dec 21, 2015 |
| M(M-251) | Aug 02, 2022 |
Drugs and Companies using OSELTAMIVIR PHOSPHATE ingredient
Market Authorisation Date: 02 July, 2007
Dosage: CAPSULE; FOR SUSPENSION
How can I launch a generic of TAMIFLU before it's drug patent expiration?
More Information on Dosage
TAMIFLU family patents
4. Xofluza patent expiration
Treatment: Method for post-exposure prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(5 years from now) | |
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(11 years from now) | |
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(11 years from now) | |
| US11925648 | GENENTECH INC | Solid dosage form having excellent stability |
Apr, 2041
(15 years from now) | |
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(5 years from now) | |
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(4 years from now) | |
| US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(12 years from now) | |
| US12064438 | GENENTECH INC | Pharmaceutical preparation excellent in light stability and dissolution property |
Oct, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
| M(M-187) | Dec 19, 2027 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Dosage: FOR SUSPENSION; TABLET
How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage
XOFLUZA family patents